Clinical investigation to modulate the effect of fenugreek polysaccharides on type-2 diabetes

Rashid, Raheela; Ahmad, Hussain; Ahmed, Zaheer; Rashid, Farhat; Khalid, Nauman

doi:10.1016/j.bcdf.2019.100194

Cited by 16 publications

(23 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For 12 weeks, patients took 1 g/day of galactomannan, the monosaccharide component of Fenugreek gum in capsule form, 1 h before meals at a set time. FBS, HbA1c, TC, TG, and LDL all significantly decreased, according to the findings [ 45 ]. Additionally, a multicenter, randomised, placebo-controlled, double-blind experiment among T2DM patients revealed that fenugreek seeds at 500 mg bid significantly lowered FBS and post-prandial plasma sugar levels [ 46 ].…”

Section: Discussionmentioning

confidence: 76%

The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial

Nematollahi

Pishdad

Zakerkish

et al. 2022

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background Type 2 Diabetes mellitus is one of the most common chronic diseases in the world and has many complications. Due to the importance of using alternative therapies in managing symptoms of this disease, the present study was designed and conducted to investigate the effect of co-supplementation of berberine and fenugreek in patients with type 2 diabetes mellitus. Methods A randomized controlled clinical trial was conducted on 50 patients with type 2 diabetes mellitus. Participants were randomized in the intervention group, which received 3 capsules/day of 500 mg (300 mg of berberine + 200 mg of fenugreek seed powder) or placebo for 12 weeks. Biochemical and anthropometric variables were measured at the beginning and end of the study. Results We observed that fasting insulin, HbA1C, and hs-CRP significantly decreased in the intervention group compared to the baseline. The mean difference in insulin resistance (-0.32 vs. 0.15), fasting blood sugar (-14.40 vs. 1.68), and fasting insulin (- 2.18 vs. 1.34) were clinically significant in comparison to the control group. Almost all domains of SF-12 scores were significantly higher in the intervention group than in the placebo group. Conclusions The combination of berberine and fenugreek seed can improve cardio-metabolic status in patients with diabetes and support the anti-diabetic and anti-inflammatory role of herb in the improvement of quality of life.

show abstract

Section: Discussionmentioning

confidence: 76%

The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial

Nematollahi

Pishdad

Zakerkish

et al. 2022

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

“…Trigonella foenum-graecum significantly reduced HbA1c (−0.6%; −0.9 to −0.4), FBG (−14 mg/dl; −22 to −5), PPBG (−21 mg/dl; −34 to −7), stimulated insulin (as insulin sensitizer; −21 mIU/L; −36 to −5), fasting C-peptide (as insulin sensitizer; −0.41 ng/ml; −0.67 to −0.16), BMI (−0.6 kg/m 2 ; −1.1 to −0.1), waist circumference (−4 cm; −7 to −1), and TG (−23 mg/dl; −46 to −1), and increased stimulated C-peptide (as insulin sensitizer; 0.93 ng/ml; 0.09–1.77) (see Figure 33 ). ( Gupta et al, 2001 ; Lu et al, 2008 ; Yaheya and Ismail, 2009 ; Ansari et al, 2011 ; Rafraf et al, 2014 ; Suchitra and Parthasarathy, 2015 ; Kaur et al, 2016 ; Singh et al, 2016 ; Verma et al, 2016 ; Ranade and Mudgalkar, 2017 ; Gholaman and Gholami, 2018 ; Kandhare et al, 2018 ; Hassani et al, 2019 ; Hota et al, 2019 ; Rashid et al, 2019 ; Hadi et al, 2020 ) Publication bias was detected in the funnel plot for HbA1c but not for FBG. In the funnel plot for HbA1c, there was an absence of smaller sized studies showing a larger positive effect, which could imply the effect may be larger than that reported from the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

Effectiveness and Safety of Ayurvedic Medicines in Type 2 Diabetes Mellitus Management: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Introduction: Many Ayurvedic medicines have the potential for managing type 2 diabetes mellitus (T2DM), with previous systematic reviews demonstrating effectiveness and safety for specific Ayurvedic medicines. However, many of the reviews need updating and none provide a comprehensive summary of all the Ayurvedic medicines evaluated for managing T2DM.Objective: The objective of this systematic review was to evaluate and synthesize evidence on the effectiveness and safety of Ayurvedic medicines for managing T2DM.Inclusion criteria: Published and unpublished RCTs assessing the effectiveness and safety of Ayurvedic medicines for managing T2DM in adults.Methods: The JBI systematic review methodology was followed. A comprehensive search of sources (including 18 electronic databases) from inception to 16 January 2021 was made. No language restrictions were applied. Data synthesis was conducted using narrative synthesis and random effects meta-analyses, where appropriate. Pooled results are reported as mean differences (MD) with 95% confidence intervals (CI).Results: Out of 32,519 records identified from the searches, 219 articles were included in the systematic review representing 199 RCTs (21,191 participants) of 98 Ayurvedic medicines. Overall, in the studies reviewed the methodology was not adequately reported, resulting in poorer methodological quality scoring. Glycated hemoglobin (HbA1c) was reduced using Aegle marmelos (L.) Corrêa (MD -1.6%; 95% CI −3 to −0.3), Boswellia serrata Roxb. (−0.5; −0.7 to −0.4), Gynostemma pentaphyllum (Thunb.) Makino (−1; −1.5 to −0.6), Momordica charantia L. (−0.3; −0.4 to −0.1), Nigella sativa L. (−0.4; −0.6 to −0.1), Plantago ovata Forssk. (−0.9; −1.4 to −0.3), Tinospora cordifolia (Willd.) Hook.f. and Thomson (−0.5; −0.6 to −0.5), Trigonella foenum-graecum L. (−0.6; −0.9 to −0.4), and Urtica dioica L. (−1.3; −2.4 to −0.2) compared to control. Similarly, fasting blood glucose (FBG) was reduced by 4–56 mg/dl for a range of Ayurvedic medicines. Very few studies assessed health-related quality of life (HRQoL). Adverse events were not reported in many studies, and if reported, these were mostly none to mild and predominately related to the gastrointestinal tract.Conclusion: The current evidence suggests the benefit of a range of Ayurvedic medicines in improving glycemic control in T2DM patients. Given the limitations of the available evidence and to strengthen the evidence base, high-quality RCTs should be conducted and reported.

show abstract

“…The violated properties are highlighted in Table . In this study, we also considered galactomannan for further study in spite of having three rules violation due to its preclinical and clinical antidiabetic reports …”

Section: Resultsmentioning

confidence: 99%

“…In this study, we also considered galactomannan for further study in spite of having three rules violation due to its preclinical and clinical antidiabetic reports. 35 For molecular docking, first we analyzed the binding pocket of the DPP-IV enzyme. The binding pocket is relatively large and is divided into five subpockets, S2 extensive, S2, S1, S′1, and S′2 subsite.…”

Section: Drug Likeness and Molecular Dockingmentioning

confidence: 99%

In Silico Molecular Docking and Dynamic Investigations of Bioactive Phytoconstituents from Fenugreek Seeds as a Potent Drug against DPP-IV Enzyme

Sarker,

Ray,

Rouf

et al. 2023

ACS Food Sci. Technol.

View full text Add to dashboard Cite

Type 2 diabetes is a metabolic disorder resulting from impaired insulin action or dysfunction in β cells. The incretin hormone, glucagon-like peptide-1, is secreted during the meal intake, and dipeptidyl peptidase IV (DPP-IV) rapidly degrades it. The discovery of new DPP-IV inhibitors from natural resources has become an attractive approach to drug discovery. The aim of this in silico study was to identify potential therapeutic lead compounds from fenugreek (Trigonella foenum-graecum) seeds. Our molecular docking study revealed that 20 compounds out of 46 reported compounds of fenugreek seeds demonstrated high affinities (−8.8 to −4.4 kcal/mol). Further molecular dynamics (MD) simulations followed by principal component analysis showed that isovitexin and deoxyrhapontin stabilized the protein quite well and manifested stable RMSD, RMSF, Rg, and SASA profiles throughout the MD simulations. The Molecular Mechanics-Poisson−Boltzmann surface area (MMPBSA) binding free energy analysis further clarified the higher binding affinity of isovitexin compared to the control.

show abstract

Clinical investigation to modulate the effect of fenugreek polysaccharides on type-2 diabetes

Cited by 16 publications

References 34 publications

The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial

The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial

Effectiveness and Safety of Ayurvedic Medicines in Type 2 Diabetes Mellitus Management: A Systematic Review and Meta-Analysis

In Silico Molecular Docking and Dynamic Investigations of Bioactive Phytoconstituents from Fenugreek Seeds as a Potent Drug against DPP-IV Enzyme

Contact Info

Product

Resources

About